{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T13:57:04Z","timestamp":1772287024623,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.msard.2019.101442","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T10:03:26Z","timestamp":1570961006000},"page":"101442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-9293","authenticated-orcid":false,"given":"Kathleen C.","family":"Munger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence M.","family":"Samkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2019.101442_bib0008","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/AOG.0000000000003176","article-title":"Immune modulating therapies in pregnancy and lactation","volume":"133","year":"2019","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.msard.2019.101442_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","article-title":"A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes","volume":"43","author":"Bandoli","year":"2017","journal-title":"Rheum. Dis. Clini. N. Am."},{"issue":"3","key":"10.1016\/j.msard.2019.101442_bib0005","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol. Neuroinflamm"},{"issue":"22","key":"10.1016\/j.msard.2019.101442_bib0003","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in neuromyelitis optica spectrum disorder","volume":"89","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2019.101442_bib0006","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1212\/NXI.0000000000000542","article-title":"Rituximab during pregnancy in neuromyelitis optica: a case report","volume":"6","author":"Miranda-Acu\u00f1a","year":"2019","journal-title":"Neurol Neuroimmunol. Neuroinflamm"},{"issue":"1","key":"10.1016\/j.msard.2019.101442_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2019.101442_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2019.101442_bib0002","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol. Neuroinflamm"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819304304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819304304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:15Z","timestamp":1761900555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819304304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":8,"alternative-id":["S2211034819304304"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101442","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101442"}}